|1.||Desai, Neil: 10 articles (07/2010 - 05/2002)|
|2.||Bhar, Paul: 6 articles (04/2013 - 09/2005)|
|3.||Soon-Shiong, Patrick: 6 articles (05/2009 - 05/2002)|
|4.||Trieu, Vuong: 5 articles (05/2009 - 06/2005)|
|5.||Ibrahim, Nuhad K: 4 articles (05/2015 - 05/2002)|
|6.||Kratz, Felix: 4 articles (09/2014 - 12/2008)|
|7.||Von Hoff, Daniel D: 4 articles (01/2014 - 11/2005)|
|8.||Gradishar, William J: 4 articles (04/2013 - 11/2005)|
|9.||Hawkins, Michael J: 4 articles (05/2008 - 11/2005)|
|10.||Cognetti, Francesco: 3 articles (04/2015 - 01/2013)|
|1.||Breast Neoplasms (Breast Cancer)
04/01/2011 - "The activity of albumin-bound paclitaxel in phase II and III trials indicates its significant clinical efficiency in the treatment of metastatic breast cancer. "
09/01/2005 - "This multicenter phase II study was designed to evaluate the efficacy and safety of ABI-007 for the treatment of metastatic breast cancer (MBC). "
04/01/2015 - "[Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer]."
02/18/2014 - "AGC patients could benefit from albumin-bound paclitaxel with lower dose level than breast cancer patients. "
07/01/2013 - "[Administration of low-dose albumin-bound paclitaxel for the treatment of advanced and recurrent breast cancer patients]."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/01/2015 - "[Complete Remission after Weekly Intravenous Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Non-Small-Cell Lung Cancer]."
05/01/2012 - "In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy."
01/01/2014 - "First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel."
05/01/2012 - "The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. "
08/01/2006 - "This multicenter phase II study was designed to evaluate the efficacy and safety of Abraxane 260 mg/m2 every 3 weeks in patients with non-small-cell lung cancer (NSCLC). "
05/01/2015 - "In this phase I pharmacokinetic study of ABI-007, which was published in the May 1, 2002, issue of Clinical Cancer Research, Ibrahim and colleagues provided the framework needed for subsequent studies to confirm the benefits of ABI-007 over solvent-based formulations. "
01/01/2011 - "The aim of this study was to investigate whether the integrin-specific PET tracer 18F-FPPRGD2 (investigational new drug 104150) can be used to monitor early response of tumors to Abraxane therapy. "
07/01/2015 - "Based on Positron Emission Tomography Response Criteria in Solid Tumors using (18)F-fluorodeoxyglucose, complete metabolic response and partial metabolic response after 2-3 courses of nanoparticle albumin-bound paclitaxel were 15.1 and 52.8%, respectively. "
07/01/2015 - "Tumor response after nanoparticle albumin-bound paclitaxel was histologically evaluated. "
01/01/2015 - "Albumin-bound paclitaxel in solid tumors: clinical development and future directions."
|4.||Lung Neoplasms (Lung Cancer)
10/27/2015 - "Abraxane, an FDA-approved albumin-bound nanoparticle (NP) form of paclitaxel (PTX) to treat breast cancer and nonsmall cell lung cancer (NSCLC), has been demonstrated to be more effective than the original Taxol, the single molecule form. "
01/01/2015 - "However, the relevance of this P-gp mediated Abraxane resistance in tumors of lung cancer patients remains unknown. "
09/01/2015 - "Case 1: An 86-year-old man was diagnosed with large cell or squamous cell lung cancer of clinical Stage II A.He was administered nanoparticle albumin-bound paclitaxel(nab-PTX)as fourth-line chemotherapy after monochemotherapy with docetaxel, vinorelbine, and S-1.The patient continues to show complete remission at the 15 courses of nab-PTX.Case"
10/01/2009 - "Abraxane, a newer, Cremophor-free form of albumin bound paclitaxel has demonstrated an activity and an improved toxicity profile in breast and lung cancers. "
01/01/2014 - "Nab-paclitaxel (Abraxane) is an albumin-bound paclitaxel that has shown clinical activity in advanced breast and lung cancer. "
|5.||Stomach Neoplasms (Stomach Cancer)
02/18/2014 - "To evaluate the safety and efficacy of albumin-bound paclitaxel in patients with advanced gastric cancer (AGC). "
02/18/2014 - "[Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients]."
02/18/2014 - "Additional phase I/II studies of albumin-bound paclitaxel in gastric cancer are warranted."
11/01/2014 - "[Nanoparticle albumin-bound Paclitaxel for unresectable or recurrent gastric cancer]."
01/01/2013 - "Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer."
|2.||130-nm albumin-bound paclitaxel
|8.||pegylated liposomal doxorubicin
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)
|4.||Combination Drug Therapy (Combination Chemotherapy)